The subcontinent of India offers a rich environment for genetic data that can enhance research into multiple rare diseases. However, that patient population is largely untapped by western pharmaceutical companies. Virginia-based IndoUSRare aims to bridge that gap and create connections that could change treatment outcomes for millions of people.
In January, ACCP published a paper that highlights the need for increased diversity in drug development. The paper, dubbed “The Importance of Diversity and Inclusion in Drug Development and Clinical Trial Conduct” recommends increasing efforts to recruit more trial patients from varying racial backgrounds.
Rare diseases impact populations across the globe, but despite that wide swath of known patients, the majority of clinical work is conducted in the United States and the European Union. There is a lack of diversity within the patient populations being tested for potential therapies, including cutting-edge gene therapies.
In Conversation: Dr. Harsha K. Rajasimha, IndoUSrare BioBuzz recently sat down for a conversation with Dr. Harsha K. Rajasimha, a leading rare disease advocate, the founder of the non-profit, IndoUSrare, [….]
